Adaptive Biotechnologies Corporation provided revenue guidance for the first quarter ended March 31, 2024. For the period, total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.18 USD | +2.25% | +13.98% | -35.10% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.10% | 469M | |
-19.60% | 10.94B | |
+64.70% | 3.75B | |
-31.09% | 2.27B | |
-10.77% | 2.25B | |
-26.86% | 1.54B | |
+35.42% | 1.18B | |
-2.40% | 754M | |
+14.91% | 340M | |
+14.40% | 224M |
- Stock Market
- Equities
- ADPT Stock
- News Adaptive Biotechnologies Corporation
- Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024